The Echidna Bayesian framework combines single-cell RNA sequencing with whole-genome sequencing to infer copy number variations and their effects on cancer cell phenotypes and drug resistance. The study uses data from endometrial cancer, glioblastoma, pancreatic cancer, non-small cell lung cancer, and melanoma to evaluate clonal reconstruction, gene dosage estimation, and tracking of metastatic or drug-resistant clones. The current implementation does not yet incorporate epigenetic regulation or single-nucleotide variants.
Source:BIOENGINEER.ORG · Read Original
Leave a Reply